HDL is hypothesized to participate in the reverse transport of cholesterol form tissues back to the liver. .
There are many lipid-lowering drugs on the market. The most common are listed below. Lipitor (atorvastatin calcium); Pravachol (pravastatin sodium); Zocor (simvastatin); and Crestor (rosuvastatin calcium). Lipitor is indicated to reduce elevated Total-C, LDL-C, Apo B and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. Pravachol is indicated to reduce elevated Total-C, LDL-C, Apo B and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. Pravachol is also indicated to reduce the risk of myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality with no increase in death from non-cardiovascular causes. It is also indicated to reduce the risk of total mortality by reducing coronary death; stroke and stroke/transient ischemic attack (TIA) and can slow the progression of coronary atherosclerosis. Zocor is indicated to reduce the risk of total mortality by reducing CHD deaths, non-fatal myocardial infarction and stroke, and need for coronary and non-coronary revascularization procedures. Patients with hypercholesterolemia Zocor is indicated to reduce elevated total-C, LDL-C Apo B, and TG, and to increase HDL-C. Crestor is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C in patients with primary hypergolesterolemia and mixed dyslipidemia. It is also indicated as an adjunct to diet for treatment of patients with elevated serum TG levels, and to reduce LDL-C, total-C, and ApoB in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments or if such treatments are unavailable. .
Doses are commonly the same. Lipitor is available in 10, 20, 40, and 80mg.